113 related articles for article (PubMed ID: 34455002)
1. Development of recombinant biomimetic nano-carrier for targeted gene transfer to HER3 positive breast cancer.
Nazari M; Minai-Tehrani A; Mousavi S; Zamani Koukhaloo S; Emamzadeh R
Int J Biol Macromol; 2021 Oct; 189():948-955. PubMed ID: 34455002
[TBL] [Abstract][Full Text] [Related]
2. Development of a ZHER3-Affibody-Targeted Nano-Vector for Gene Delivery to HER3-Overexpressed Breast Cancer Cells.
Nazari M; Zamani Koukhaloo S; Mousavi S; Minai-Tehrani A; Emamzadeh R; Cheraghi R
Macromol Biosci; 2019 Nov; 19(11):e1900159. PubMed ID: 31531954
[TBL] [Abstract][Full Text] [Related]
3. Cellular effects of HER3-specific affibody molecules.
Göstring L; Malm M; Höidén-Guthenberg I; Frejd FY; Ståhl S; Löfblom J; Gedda L
PLoS One; 2012; 7(6):e40023. PubMed ID: 22768204
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the Therapeutic Potential of a HER3-Binding Affibody Construct TAM-HER3 in Comparison with a Monoclonal Antibody, Seribantumab.
Orlova A; Bass TZ; Rinne SS; Leitao CD; Rosestedt M; Atterby C; Gudmundsdotter L; Frejd FY; Löfblom J; Tolmachev V; Ståhl S
Mol Pharm; 2018 Aug; 15(8):3394-3403. PubMed ID: 29995421
[TBL] [Abstract][Full Text] [Related]
5. A recombinant affitoxin derived from a HER3 affibody and diphteria-toxin has potent and selective antitumor activity.
Nazari M; Emamzadeh R; Jahanpanah M; Yazdani E; Radmanesh R
Int J Biol Macromol; 2022 Oct; 219():1122-1134. PubMed ID: 36041577
[TBL] [Abstract][Full Text] [Related]
6. Inhibiting HER3-mediated tumor cell growth with affibody molecules engineered to low picomolar affinity by position-directed error-prone PCR-like diversification.
Malm M; Kronqvist N; Lindberg H; Gudmundsdotter L; Bass T; Frejd FY; Höidén-Guthenberg I; Varasteh Z; Orlova A; Tolmachev V; Ståhl S; Löfblom J
PLoS One; 2013; 8(5):e62791. PubMed ID: 23675426
[TBL] [Abstract][Full Text] [Related]
7. Comparative evaluation of 111In-labeled NOTA‑conjugated affibody molecules for visualization of HER3 expression in malignant tumors.
Andersson KG; Rosestedt M; Varasteh Z; Malm M; Sandström M; Tolmachev V; Löfblom J; Ståhl S; Orlova A
Oncol Rep; 2015 Aug; 34(2):1042-8. PubMed ID: 26059265
[TBL] [Abstract][Full Text] [Related]
8. Imaging of HER3-expressing xenografts in mice using a (99m)Tc(CO) 3-HEHEHE-Z HER3:08699 affibody molecule.
Orlova A; Malm M; Rosestedt M; Varasteh Z; Andersson K; Selvaraju RK; Altai M; Honarvar H; Strand J; Ståhl S; Tolmachev V; Löfblom J
Eur J Nucl Med Mol Imaging; 2014 Jul; 41(7):1450-9. PubMed ID: 24622956
[TBL] [Abstract][Full Text] [Related]
9. Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer.
Watanabe S; Yonesaka K; Tanizaki J; Nonagase Y; Takegawa N; Haratani K; Kawakami H; Hayashi H; Takeda M; Tsurutani J; Nakagawa K
Cancer Med; 2019 Mar; 8(3):1258-1268. PubMed ID: 30701699
[TBL] [Abstract][Full Text] [Related]
10. Engineering multivalent antibodies to target heregulin-induced HER3 signaling in breast cancer cells.
Kang JC; Poovassery JS; Bansal P; You S; Manjarres IM; Ober RJ; Ward ES
MAbs; 2014; 6(2):340-53. PubMed ID: 24492289
[TBL] [Abstract][Full Text] [Related]
11. Silencing human epidermal growth factor receptor-3 radiosensitizes human luminal A breast cancer cells.
He G; Di X; Yan J; Zhu C; Sun X; Zhang S
Cancer Sci; 2018 Dec; 109(12):3774-3782. PubMed ID: 30259607
[TBL] [Abstract][Full Text] [Related]
12. Increase in negative charge of
Rinne SS; Dahlsson Leitao C; Gentry J; Mitran B; Abouzayed A; Tolmachev V; Ståhl S; Löfblom J; Orlova A
Sci Rep; 2019 Nov; 9(1):17710. PubMed ID: 31776413
[TBL] [Abstract][Full Text] [Related]
13. Development of a genetically engineered biomimetic vector for targeted gene transfer to breast cancer cells.
Mangipudi SS; Canine BF; Wang Y; Hatefi A
Mol Pharm; 2009; 6(4):1100-9. PubMed ID: 19419197
[TBL] [Abstract][Full Text] [Related]
14. Targeting and suppression of HER3-positive breast cancer by T lymphocytes expressing a heregulin chimeric antigen receptor.
Zuo BL; Yan B; Zheng GX; Xi WJ; Zhang X; Yang AG; Jia LT
Cancer Immunol Immunother; 2018 Mar; 67(3):393-401. PubMed ID: 29127433
[TBL] [Abstract][Full Text] [Related]
15. The interplay of HER2/HER3/PI3K and EGFR/HER2/PLC-γ1 signalling in breast cancer cell migration and dissemination.
Balz LM; Bartkowiak K; Andreas A; Pantel K; Niggemann B; Zänker KS; Brandt BH; Dittmar T
J Pathol; 2012 Jun; 227(2):234-44. PubMed ID: 22262199
[TBL] [Abstract][Full Text] [Related]
16. Perhexiline promotes HER3 ablation through receptor internalization and inhibits tumor growth.
Ren XR; Wang J; Osada T; Mook RA; Morse MA; Barak LS; Lyerly HK; Chen W
Breast Cancer Res; 2015 Feb; 17(1):20. PubMed ID: 25849870
[TBL] [Abstract][Full Text] [Related]
17. Improved contrast of affibody-mediated imaging of HER3 expression in mouse xenograft model through co-injection of a trivalent affibody for in vivo blocking of hepatic uptake.
Rosestedt M; Andersson KG; Rinne SS; Leitao CD; Mitran B; Vorobyeva A; Ståhl S; Löfblom J; Tolmachev V; Orlova A
Sci Rep; 2019 May; 9(1):6779. PubMed ID: 31043683
[TBL] [Abstract][Full Text] [Related]
18. Transphosphorylation of kinase-dead HER3 and breast cancer progression: a new standpoint or an old concept revisited?
Menendez JA; Lupu R
Breast Cancer Res; 2007; 9(5):111. PubMed ID: 17983482
[TBL] [Abstract][Full Text] [Related]
19. Resistance to receptor-blocking therapies primes tumors as targets for HER3-homing nanobiologics.
Sims JD; Taguiam JM; Alonso-Valenteen F; Markman J; Agadjanian H; Chu D; Lubow J; Abrol R; Srinivas D; Jain A; Han B; Qu Y; Mirzadehgan P; Hwang JY; Rentsendorj A; Chung A; Lester J; Karlan BY; Gray HB; Gross Z; Giuliano A; Cui X; Medina-Kauwe LK
J Control Release; 2018 Feb; 271():127-138. PubMed ID: 29288681
[TBL] [Abstract][Full Text] [Related]
20. Affibody-Conjugated RALA Polymers Delivering Oligomeric 5-Fluorodeoxyuridine for Targeted Therapy of HER2 Overexpressing Gastric Cancer.
Zhang F; Yin J; Zhang C; Han M; Wang X; Fu S; Du J; Zhang H; Li W
Macromol Biosci; 2020 Jul; 20(7):e2000083. PubMed ID: 32558229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
